Skip to main content

Table 1 Combination index (CI) and dose reduction index (DRI) values for drugs combinations schedule after 72 h of simultaneous treatment.

From: Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205

Drugs

Molar ratio

CI ± SD at Fraction affected level

DRI ± SD at Fraction affected level

   

25%

50%

75%

25%

50%

75%

I

II

 

I+II

I+II

I+II

I

II

I

II

I

II

5-FU

Decytabine

1.7:1

0.25 ± 0.1*

0.36 ± 0.1*

0.63 ± 0.3*

6.38 ± 1.9*

12.8 ± 5*

3.4 ± 0.7*

14.1 ± 3.1*

2.3 ± 0.6*

22.7 ± 9

 

Zebularine

1.7:1

1.24 ± 0.2

0.76 ± 0.1*

0.68 ± 0.1

N/D

N/D

1.9 ± 0.7*

4.6 ± 1.8*

4.1 ± 2

2.2 ± 0.5*

Oxaliplatin

Decytabine

1:2

0.28 ± 0.1*

0.17 ± 0.1*

0.12 ± 0.1*

0.83 ± 0.4*

1.4 ± 0.4*

4.3 ± 0.43*

12.2 ± 3.1

N/A

N/A

 

Zebularine

1:2

0.29 ± 0.3*

2.90 ± 0.5*

N/A

0.47 ± 0.3

1.3 ± 0.7

N/D

N/D

N/D

N/D

  1. Data are expressed as means ± SD (n = 8 for CI; n ≥ 3 for DRI). *, p < 0.05; N/D, not determined; N/A, not achieved at the highest concentration tested. A CI value significantly less than 1 indicates synergy, a CI not significantly different from 1 indicates addition, and a CI significantly higher than 1 indicates antagonism. The DRI determines the magnitude of dose reduction allowed for each drug when given in synergistic combination, as compared with the concentration of a single agent that is needed to achieve the same effect. 25, 50 and 75% indicates selected values of fraction affected level.
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us